Risti B, Flury R F, Schaffner A
Department of Medicine, University of Zürich Medical School, Switzerland.
Clin Investig. 1994 Jun;72(6):457-61. doi: 10.1007/BF00180521.
Fatal hematophagic histiocytosis occurred in two patients after they had received granulocyte-macrophage colony-stimulating factor (GM-CSF) in addition to chemotherapy for malignant non-Hodgkin's lymphoma. In one patient GM-CSF promoted the activity of subclinical hematophagic histiocytosis, resulting in severe pancytopenia and multiorgan failure. In the other patient the syndrome that caused persistent bone marrow failure began after the institution of GM-CSF therapy. Exogenous GM-CSF appears to upregulate preexisting hematophagic histiocytosis and may even contribute to its de novo initiation. It is therefore conceivable that endogenous GM-CSF also plays an essential role in the pathogenesis of this syndrome.
两名恶性非霍奇金淋巴瘤患者在接受化疗的同时还接受了粒细胞巨噬细胞集落刺激因子（GM-CSF）治疗后发生了致命性噬血细胞组织细胞增生症。在一名患者中，GM-CSF促进了亚临床噬血细胞组织细胞增生症的活动，导致严重全血细胞减少和多器官功能衰竭。在另一名患者中，导致持续性骨髓衰竭的综合征在GM-CSF治疗开始后出现。外源性GM-CSF似乎上调了预先存在的噬血细胞组织细胞增生症，甚至可能导致其从头发生。因此，可以想象内源性GM-CSF在该综合征的发病机制中也起着重要作用。
